ReviewPharmaceuticals (Basel, Switzerland)2021
Metabolic Host-Microbiota Interactions in Autophagy and the Pathogenesis of Inflammatory Bowel Disease (IBD).
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Article
- Autotaxin-Scavenging Nanoliposomes for Prolonged Colon Retention and Autophagy-Mediated Mucosal Immune Restoration in Colitis.Biomaterials research · 2026Article
- Apoptosis-related genes bridge inflammatory bowel disease and osteoporosis: A bioinformatic analysis.PloS one · 2026Article
- Article
- Isolation and Probiotic Functions ofBiology · 2025Article
- Role of gut microbiota in the development of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.World journal of gastroenterology · 2025Review
- Obesity-Mediated Inflammation and Its Influence on Inflammatory Bowel Disease: Pathophysiology, Clinical Impact, and Therapeutic Implications.Biomolecules · 2025Review
- Microbial trash to metabolic treasure.Immunometabolism (Cobham, Surrey) · 2025Article
- Human umbilical cord mesenchymal stem cell-derived exosomes repair IBD by activating the SIRT1-FXR pathway in macrophages.Stem cell research & therapy · 2025Article
- Autophagy: a double-edged sword in ischemia-reperfusion injury.Cellular & molecular biology letters · 2025Review
- Korean Mistletoe (Antioxidants (Basel, Switzerland) · 2025Article
- Ginseng exosomes modulate M1/M2 polarisation by activating autophagy and target IKK/IкB/NF-кB to alleviate inflammatory bowel disease.Journal of nanobiotechnology · 2025Article
- Lily polysaccharides alleviate colitis through the microbiota-N8-acetylspermidine-cGAS-STING signaling axis.Frontiers in microbiology · 2025Article
- A synbiotic combination of mixed probiotics and oligofructose restores intestinal microbiota disturbance in DSS-induced colitis in mice.Frontiers in microbiology · 2025Article
- Autophagy in inflammatory bowel disease: immunization, etiology, and therapeutic potential.Frontiers in immunology · 2025Review
- More on the interplay between gut microbiota, autophagy, and inflammatory bowel disease is needed.World journal of gastroenterology · 2024Review
- Exploring host-commensal-pathogen dynamics in cell line and organotypic human intestinal epithelial models.iScience · 2024Article
- Modulation of Serotonin-Related Genes by Extracellular Vesicles of the ProbioticInternational journal of molecular sciences · 2024Article
- Extrachromosomal Circular DNA: An Emerging Potential Biomarker for Inflammatory Bowel Diseases?Genes · 2024Review
- The involvement of oral bacteria in inflammatory bowel disease.Gastroenterology report · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Inflammatory bowel disease (IBD) is a family of conditions characterized by chronic, relapsing inflammation of the gastrointestinal tract. IBD afflicts over 3 million adults in the United States and shows increasing prevalence in the Westernized world. Current IBD treatments center on modulation of the damaging inflammatory response and carry risks such as immunosuppression, while the development of more effective treatments is hampered by our poor understanding of the molecular mechanisms of IBD pathogenesis. Previous genome-wide association studies (GWAS) have demonstrated that gene variants linked to the cellular response to microorganisms are most strongly associated with an increased risk of IBD. These studies are supported by mechanistic work demonstrating that IBD-associated polymorphisms compromise the intestine's anti-microbial defense. In this review, we summarize the current knowledge regarding IBD as a disease of defects in host-microbe interactions and discuss potential avenues for targeting this mechanism for future therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.